Skip to main content

Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026

Data build on findings presented at ESMO 2025 and support potential of darlifarnib to overcome resistance and resensitize tumors to VEGFR TKI therapy Virtual investor call on April 17, 2026, at 7:30 a.m. PT / 10:30 a.m. ET / 4:30 p.m. CEST SAN DIEGO, April 09, 2026 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced it will present updated data from its ongoing FIT-001 clinical trial (NCT 06026410) evaluating darlifarnib (KO-2806) in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma at the International Kidney Cancer Symposium (IKCS) Europe 2026 in Paris, France. The data to be presented build on earlier findings from the FIT-001 study reported at the 2025 European Society for Medical Oncology...

Continue reading

Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline

Seasoned biotech executive brings deep experience across clinical development, regulatory strategy, and corporate operations, strengthening execution capabilities as Plus advances REYOBIQ™ and CNS-focused pipeline HOUSTON, April 09, 2026 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announced the appointment of Eric J. Daniels, M.D., MBA, as Chief Development Officer, effective April 20, 2026. Dr. Daniels is a seasoned biotechnology executive with more than two decades of experience spanning clinical development, regulatory strategy, corporate operations, and business development. He most recently served as Chief Development Officer at Kiora...

Continue reading

Dynacor Group Announces CEO Transition

MONTREAL, April 09, 2026 (GLOBE NEWSWIRE) — Dynacor Group Inc. (TSX: DNG) (“Dynacor“ or the “Corporation“) announces that Jean Martineau, who has served as President and CEO since 2007 will retire from the Corporation immediately following the June 2026 Annual Shareholder Meeting (“AGM”). As part of the Corporation’s succession planning, Daniel Misiano, who has served as the COO since 2024, will assume the role of President & CEO at that time. Mr. Martineau will stand for election to the Dynacor Board of Directors (“Board”) at the AGM. “Serving Dynacor for nearly two decades has been a joy and a privilege,” said Jean Martineau, President & CEO. “Since its start-up, we have scaled the business far beyond what we envisioned, growing operations ten-fold while maintaining a solid balance sheet and expanding...

Continue reading

AMN Healthcare to Hold First Quarter 2026 Earnings Conference Call on Thursday, May 7, 2026

DALLAS, April 09, 2026 (GLOBE NEWSWIRE) — AMN Healthcare Services, Inc. (NYSE: AMN), has scheduled a conference call to discuss its first quarter 2026 financial results and second quarter 2026 outlook on Thursday, May 7, 2026, at 5:00 p.m. Eastern Time. On the same day, the Company also expects to issue an earnings news release after market close at approximately 4:15 p.m. Eastern Time. A live webcast of the call can be accessed through this webcast link, which also will be available on AMN Healthcare’s investor relations website. Interested parties may participate live via telephone by registering at this conference call link. Please follow the link and register with a valid e-mail address. A PIN will be provided to you with dial-in instructions. If you lose track of these details, please re-register at the conference call link...

Continue reading

Big Bear Gold Corp. Announces AGM Results and Adoption of Omnibus Long-Term Incentive Plan

Vancouver, BC, April 09, 2026 (GLOBE NEWSWIRE) — Big Bear Gold Corp. (TSXV: BEAR) (the “Company”) wishes to announce the results of its 2026 annual general meeting of shareholders (the “2026 AGM”) held on April 6, 2026.  Shareholders voted in favour of all matters brought before the meeting, including re-appointing Davidson & Company LLP, as the Company’s auditor and approving the Company’s new Omnibus Long-Term Incentive Plan (the “Omnibus Plan”).  In addition, Peter Laipnieks, Corey Klassen, Allen Schwabe and Matt Wayrynen were all re-elected as directors of the Company. The Omnibus Plan provides the Company with a variety of security-related mechanisms to attract, retain, and motivate qualified directors, employees, and consultants.  The Omnibus Plan replaced the Company’s prior stock option plan and includes (i) a 10% “rolling”...

Continue reading

NIOB Authorized to Drill at Two More Québec Projects

Fully permitted for diamond drilling on niobium and rare earth targets at Seigneurie, Bardy and Blanchette Vancouver, British Columbia, April 09, 2026 (GLOBE NEWSWIRE) — North American Niobium and Critical Minerals Corp. (CSE: NIOB) (FSE: KS82.F) (OTCQB: NIOMF) (“NIOB” or the Company) can launch maiden diamond drill programs at Bardy and Blanchette, after receiving an Authorization for Impact-Causing Exploration Work (ATI) for each project. Granted by Québec’s Ministère des Ressources naturelles et des Forêts (MRNF), the ATI authorizes the Company to proceed with diamond drilling targeting niobium and rare earth element mineralization at the 100% owned projects located approximately 45 km northwest of La Tuque in the Mauricie region. “We are now authorized to drill at three of our 100% owned projects in Québec: Bardy, Blanchette,...

Continue reading

InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor

JENA, Germany, April 09, 2026 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced new in vitro findings demonstrating that izicopan does not exhibit time-dependent inhibition of CYP3A4, an important indicator for the risk for drug-drug interactions (DDIs) and liver toxicity. These results further support izicopan’s potential as a differentiated, best-in-class oral C5a receptor (C5aR) inhibitor. To build upon previous CYP interaction data for izicopan, which showed only marginal inhibition of CYP3A4 (IC₅₀ = 62 µM) in a time-dependent inhibition (TDI) IC₅₀ shift assay, InflaRx conducted a mechanistically informative Ki-based TDI (Ki/Kinact) study. While TDI shift assays serve as rapid screening tools to identify potential...

Continue reading

AGA Precision Systems Signs Second Long-Term Supply Agreement to Manufacture Aerospace and Defense Components for a Tier 1 Firm

Signing of Second Long-Term Agreement with Major Aerospace and Defense Customer in 2026, Demonstrating Continued Customer Confidence and Contract Momentum NEWPORT BEACH, Calif., April 09, 2026 (GLOBE NEWSWIRE) — AGA Precision Systems LLC (“AGA”), an ITAR-registered and AS9100-certified precision CNC aerospace and defense manufacturing company and subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), today announced the execution of a Long-Term Agreement (“LTA”) with globally recognized Tier 1 aerospace and defense company. The LTA formalizes an ongoing multi-year supplier-customer relationship and governs future purchase orders issued during its term. This marks AGA’s second long-term agreement with an aerospace and defense customer, following the execution of an LTA with Turbo-Jet Products Co., Inc. announced March 31, 2026, and reflects...

Continue reading

Bombardier to Report First Quarter 2026 Financial Results and Host Annual General Meeting of Shareholders on April 30, 2026

MONTREAL, April 09, 2026 (GLOBE NEWSWIRE) — Bombardier (TSX: BBD.B) will publish its financial results for the first quarter of 2026 on April 30, 2026. That same day, Bombardier will hold its Annual General Meeting of Shareholders (“Meeting”) in a virtual format. Financial results for the first quarter of 2026 Éric Martel, President and Chief Executive Officer, Bombardier, and Bart Demosky, Executive Vice President and Chief Financial Officer, Bombardier, will present the financial results for the first quarter of 2026 in a live presentation, followed by a question-and-answer period with analysts. The presentation will take place on April 30, 2026, at 8:00 a.m. ET. To listen in:Live webcast (recommended):A live webcast of the financial results presentation, along with the relevant financial charts, will be available on this webpage.By...

Continue reading

Bitcoin Bancorp Launches California Deployment of Licensed Bitcoin ATM Network With First Installations

Initial Southern California deployment marks next phase of national retail expansion LAS VEGAS, April 09, 2026 (GLOBE NEWSWIRE) — Bitcoin Bancorp, Inc. (OTC: BCBC) (“Bitcoin Bancorp” or the “Company”), the holder of foundational patents for Bitcoin ATMs, and one of only three publicly traded Bitcoin ATM network owner/operators, today announced the initial deployment of licensed Bitcoin ATMs in Southern California. The Company has completed its first installations in the greater Los Angeles area, marking the next phase of its national expansion strategy. This move follows its previously announced rollout in Texas and represents continued execution of a broader plan to scale its Bitcoin ATM network across key U.S. retail markets. The Bitcoin ATM industry continues its rapid expansion, with the U.S. crypto ATM market valued at approximately...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.